Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Protalix Biotherapeutics (PLX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 100,512
  • Shares Outstanding, K 144,000
  • Annual Sales, $ 9,200 K
  • Annual Income, $ -29,370 K
  • 36-Month Beta 0.97
  • Price/Sales 5.42
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.22
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/15/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.59 +20.14%
on 12/20/17
0.76 -7.19%
on 01/05/18
+0.11 (+18.33%)
since 12/19/17
3-Month
0.58 +22.41%
on 12/19/17
0.81 -12.35%
on 10/20/17
-0.07 (-8.97%)
since 10/19/17
52-Week
0.48 +47.92%
on 08/24/17
1.51 -52.98%
on 03/14/17
+0.20 (+39.22%)
since 01/19/17

Most Recent Stories

More News
Biotech and Pain Management Therapeutics Segments Projected to Grow

According to EP Vantage, the editorial arm of Evaluate Ltd., in 2017 the FDA has given green light to 43 novel drugs, which are forecast to be generating a combined $32bn in US sales in five-years' time....

SBOT : 0.91 (-2.77%)
BICX : 0.2400 (+11.63%)
RGLS : 1.40 (+0.72%)
PTN : 0.88 (unch)
PLX : 0.71 (+1.72%)
Protalix BioTherapeutics Reports Positive Interim Data from Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis

Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), announced today interim data from the first 14 patients that completed, to date, the Company's phase II clinical trial of OPRX-106 (oral anti-TNF)...

PLX : 0.71 (+1.72%)
Wired News - Protalix BioTherapeutics Granted Orphan Drug Designation for the Treatment of Fabry Disease

LONDON, UK / ACCESSWIRE / December 29, 2017 / Active-Investors.com has just released a free research report on Protalix BioTherapeutics, Inc. (NYSE: PLX). If you want access to this report all you need...

PLX : 0.71 (+1.72%)
Protalix (PLX) Fabry Disease Candidate Gets Orphan Status

Protalix BioTherapeutics's (PLX) pipeline candidate, PRX-102, gets orphan drug status in Europe which is being developed as a treatment for Fabry disease.

SHPG : 144.99 (-0.48%)
PLX : 0.71 (+1.72%)
PFE : 36.94 (-0.14%)
SNY : 44.60 (+0.20%)
Protalix BioTherapeutics' PRX-102 Granted Orphan Drug Designation by the European Commission

Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary...

PLX : 0.71 (+1.72%)
Technical Perspectives on Protalix BioTherapeutics, 22nd Century, CorMedix, and iBio

In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on PLX, XXII, CRMD, and IBIO which is a click away at www.wallstequities.com/registration....

XXII : 3.86 (+1.05%)
CRMD : 0.49 (+2.08%)
IBIO : 0.18 (unch)
PLX : 0.71 (+1.72%)
Protalix BioTherapeutics Completes Enrollment in Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis

Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), announced today the completion of enrollment in the Company's phase II clinical trial evaluating OPRX-106, the Company's oral antiTNF product...

PLX : 0.71 (+1.72%)
Protalix BioTherapeutics Presents Positive Results from the Phase I/II Open-Label Extension Trial for PRX-102 at the New Horizons for Fabry Disease Conference

Continued to Demonstrate Improvement across all Key Fabry Disease Parameters at 24 Months

PLX : 0.71 (+1.72%)
Global Biotechnology Market Showing Potential for Further Growth

According to a report by Global Market Insights, Inc., the Biotechnology Market size will exceed USD 775.2 billion with 9.9% CAGR from 2016 to 2024. Based on technology, the industry is segmented into...

ADMP : 4.35 (+3.57%)
COSM : 10.7900 (unch)
INFI : 2.04 (+0.49%)
CASI : 4.09 (+2.76%)
PLX : 0.71 (+1.72%)
Protalix BioTherapeutics Announces Presentation to be made at the New Horizons in Fabry Disease Conference

Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX) announced today two-year results from the phase I/II open-label extension clinical trial of pegunigalsidase alfa, or PRX-102, for the treatment...

PLX : 0.71 (+1.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx(R). Protalix's unique expression system presents a proprietary method for developing recombinant...

See More

Key Turning Points

2nd Resistance Point 0.74
1st Resistance Point 0.72
Last Price 0.71
1st Support Level 0.69
2nd Support Level 0.68

See More

52-Week High 1.51
Fibonacci 61.8% 1.12
Fibonacci 50% 1.00
Fibonacci 38.2% 0.87
Last Price 0.71
52-Week Low 0.48

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.